Otolaryngology ·
Oral orforglipron cuts sleep apnea events in ATTAIN-OSA; preoperative grading system stratifies sinus surgery outcomes

Listen to this post
read by AI voices · all episodesTHE SHORT READ
Once-daily oral orforglipron cut about 18 breathing interruptions per hour versus about five with placebo in the 712-patient ATTAIN-OSA trials, published in JAMA. A preoperative grading system for endoscopic sinus surgery separated patients by their chance of meaningful improvement, and a database study examined non-opioid analgesia guidelines in pediatric adenotonsillectomy.
THE DETAILS
- Research Nov 9, 2026In two randomized trials in adults with moderate to severe obstructive sleep apnea and excess weight, one in CPAP users, the once-daily oral GLP-1 drug group had about 18 fewer breathing interruptions per hour of sleep at 52 weeks versus about five fewer with placebo, according to the American Heart Association (AHA). Eli Lilly said the apnea-hypopnea index fell 21.1 events per hour without positive airway pressure and 18.3 with it. Body weight fell about 10% to 11% with orforglipron. Nausea, diarrhea and constipation were most common. The results were presented Nov. 9 and published in JAMA.Sources: American Heart Association, Eli Lilly
- Research Nov 12, 2026A prospective cohort study published online in JAMA Otolaryngology-Head & Neck Surgery on Nov. 12 analyzed 450 patients with chronic rhinosinusitis at academic tertiary care rhinology clinics who had complete clinical and imaging grading data before endoscopic sinus surgery. Of them, 64% achieved clinically meaningful improvement, defined as a Sino-Nasal Outcome Test improvement of at least 8.9 points, ranging from 81% (95% CI 72% to 88%) at grade 1 to 29% (95% CI 19% to 40%) at grade 4, a 52.5-percentage-point risk difference. The authors said that if validated externally, the system may support preoperative counseling and clinical trial stratification.
- Research Nov 10, 2026A retrospective cohort study published online in Otolaryngology-Head and Neck Surgery on Nov. 10 used TriNetX, a multi-institutional federated electronic health record database, to assess opioid-sparing analgesia in pediatric adenotonsillectomy after the 2019 American Academy of Otolaryngology-Head and Neck Surgery clinical practice guideline, with 66,844 patients in each propensity-matched cohort. The pre-2019 cohort had a higher risk of dehydration (risk ratio 1.27, 95% CI 1.17 to 1.38). The authors reported a number needed to treat of 101.7 to prevent one emergency department visit and an estimated $3.2 million in cost avoidance within the studied cohort.Sources: Otolaryngology-Head and Neck Surgery, PubMed
The weekly innovation roundup for otolaryngology, published every Sunday for the week before; every item links to its sources. Latest otolaryngology news · All specialties